- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
2.—(1) Schedule 2 to the Misuse of Drugs Act 1971 (which specifies the drugs which are subject to control under that Act) is amended as follows.
(2) In Part 2 (Class B drugs)—
(a)after paragraph 1(b), insert—
“(c)[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.
3–Dimethylheptyl–11–hydroxyhexahydrocannabinol.
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.
9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.
Nabilone.
Any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”;
(b)in paragraph 2A, after “derivative” insert “or of a substance for the time being specified in paragraph 1(c) of this Part of this Schedule.”.
(3) In Part 3 (Class C drugs)—
(a)in paragraph 1(a), after “Flurazepam”, insert “Gamma–butyrolactone”;
(b)in paragraph 1(b)—
(i)before “4–Androstene–3,17–dione”, insert—
“5α–Androstane–3,17–diol.
Androst-4-ene-3,17-diol.
1–Androstenediol.
1–Androstenedione”;
(ii)after “4–Androstene–3,17–dione”, insert “5–Androstenedione.”;
(iii)after “Boldenone.”, insert “Boldione.”;
(iv)after “Bolmantalate.”, insert “1,4–Butanediol.”;
(v)after “Clostebol.”, insert—
“Danazol.
Desoxymethyltestosterone”;
(vi)after “Furazabol.”, insert—
“Gestrinone.
3–Hydroxy–5α–androstan–17–one.”;
(vii)after “Nandrolone.”, insert “19–Norandrostenedione.”;
(viii)after “19–Nor–5–Androstene–3,17–diol”, insert “19–Norandrosterone.”;
(ix)after “Norethandrolone.”, insert—
“19–Noretiocholanolone.
Oripavine.”;
(x)after “Propetandrol.”, insert “Prostanozol.”;
(xi)after “Testosterone.”, insert “Tetrahydrogestrinone.”;
(c)after paragraph 1(c), insert—
“(ca)1–benzylpiperazine or any compound structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—
(i)by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
(ii)by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups.”;
(d)in paragraph 1(e), after “Somatropin.”, insert “Zeranol.” and “Zilpaterol.”.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: